Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

62.13USD
14 Dec 2017
Change (% chg)

$-1.34 (-2.11%)
Prev Close
$63.47
Open
$63.18
Day's High
$63.50
Day's Low
$61.72
Volume
1,682,980
Avg. Vol
1,481,352
52-wk High
$66.09
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs .Under the terms of this agreement, BMS is granted the rights to develop and commercialize ONO-4578 and other compounds from PGE2 receptor antagonist programs worldwide, except Japan, South Korea, Taiwan, China and Association of South-East Asian Nations (ASEAN)countries.In accordance with this agreement, ONO receives an upfront payment of $40 million from BMS.ONO will also receive subsequent clinical, regulatory and sales-based milestone payments, as well as royalties based on sales of the products in the countries where ONO granted BMS the rights for development and commercialization.  Full Article

Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.BRISTOL-MYERS SQUIBB-WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING,COMMERCIALIZATION OF ONO-4578,OTHER PGE(2) RECEPTOR ANTAGONIST PRODUCTS.  Full Article

U.S. FDA Accepts Bristol-Myers Squibb’S Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Bristol-Myers Squibb Co ::U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AND GRANTS PRIORITY REVIEW.BRISTOL-MYERS SQUIBB CO - APPLICATION HAS AN ACTION DATE OF APRIL 16, 2018.BRISTOL-MYERS SQUIBB CO - APPLICATION BASED ON RESULTS FROM PHASE 3 CHECKMATE -214 STUDY.  Full Article

Bristol-Myers Squibb Announces 2.6 Pct Increase In Quarterly Dividend Beginning Q1 2018
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES DIVIDEND INCREASE.BRISTOL-MYERS SQUIBB CO - AN INCREASE OF 2.6% PERCENT IN COMPANY'S QUARTERLY DIVIDEND, BEGINNING IN Q1 OF 2018.BRISTOL-MYERS SQUIBB CO - DIVIDEND INCREASE WILL RESULT IN A QUARTERLY DIVIDEND OF 40 CENTS.  Full Article

Ayala Enters Exclusive Worldwide License Agreement With Bristol-Myers Squibb
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Ayala Pharmaceuticals::AYALA PHARMACEUTICALS, FOUNDED BY ISRAEL BIOTECH FUND, AMOON AND HAREL INSURANCE, ENTERS EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB (BMS) TO DEVELOP CANCER TREATMENTS.‍SAYS WILL HAVE EXCLUSIVE WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION RIGHTS FOR BMS-906024 AND BMS-986115​.SAYS CO IS RESPONSIBLE FOR ALL FUTURE DEVELOPMENT AND COMMERCIALIZATION OF BMS-906024 AND BMS-986115.SAYS IN CONNECTION WITH LICENSE, BMS RECEIVED UPFRONT PAYMENT, BECAME A SHAREHOLDER OF CO.SAYS ‍PLAN TO INITIATE PHASE 2 CLINICAL TRIALS IN 2018​.SAYS IN CONNECTION WITH LICENSE, BMS TO ALSO RECEIVE CERTAIN DEVELOPMENT, REGULATORY, SALES-BASED MILESTONES, TIERED ANNUAL NET SALES ROYALTIES.  Full Article

Bristol-Myers says Checkmate -078 trial stopped early for demonstrating superior overall survival
Friday, 1 Dec 2017 

Nov 30 (Reuters) - Bristol-Myers Squibb Co ::CHECKMATE -078, A PIVOTAL, MULTINATIONAL PHASE 3 OPDIVO (NIVOLUMAB) LUNG CANCER TRIAL WITH PREDOMINANTLY CHINESE PATIENTS, STOPPED EARLY FOR DEMONSTRATING SUPERIOR OVERALL SURVIVAL.‍CHINA FOOD AND DRUG ADMINISTRATION ACCEPTED MARKETING APPLICATION FOR OPDIVO​.‍SAFETY PROFILE OF OPDIVO WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES IN SOLID TUMORS​.BRISTOL-MYERS- OPDIVO SHOWS SUPERIOR OVERALL SURVIVAL COMPARED TO DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER​.  Full Article

Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC.CYTOMX THERAPEUTICS INC - ‍IND ACCEPTANCE RESULTS IN A $10 MILLION MILESTONE PAYMENT TO CYTOMX​.CYTOMX THERAPEUTICS INC - ‍BRISTOL-MYERS SQUIBB HAS RECEIVED ACCEPTANCE OF IND FROM U.S. FDA FOR A CTLA-4-DIRECTED PROBODY THERAPEUTIC​.  Full Article

Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo®.Laboratory Corporation Of America Holdings - ‍announced U.S. availability of PD-L1 ihc 28-8 pharmdx assay as complementary diagnostic for 2 indications in connection with use of Opdivo​.  Full Article

Bristol-Myers and Syngene expand ongoing research collaboration
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Syngene International ::Bristol-Myers Squibb and Syngene International expand ongoing research collaboration.Says collaboration with Bristol-Myers Squibb extended until 2026​.  Full Article

Syngene International ‍expands collaboration with Bristol-Myers Squibb​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Syngene International Ltd ::Says ‍expanded collaboration with Bristol-Myers Squibb​.Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations​.  Full Article

BRIEF-Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists

* Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs